ABCSG 60 / CAMBRIA-1 Overview

A phase III, open-label, randomized study to assess the efficacy and safety of extended therapy with camizestrant versus standard endocrine therapy in patients with ER+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed at least 2 years of standard adjuvant endocrine-based therapy without disease recurrence.

Start: (global): 03/2023; FPI 04/2023
(national): 07/2023
Coordinating Investigator AT: Daniel Egle, Innsbruck
Sample: 4300 (global),
100 (national)
Study design:
(Click to enlarge)
ABCSG 60 / CAMBRIA-1 Design

Share on